Scarica l'app Stockscreener
28.09
4.91%
-1.45
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$29.54
Aprire:
$29.54
Volume 24 ore:
465.20K
Relative Volume:
1.35
Capitalizzazione di mercato:
$519.10M
Reddito:
$294.28M
Utile/perdita netta:
$367.02M
Rapporto P/E:
1.4853
EPS:
18.9115
Flusso di cassa netto:
$75.66M
1 W Prestazione:
-8.08%
1M Prestazione:
+2.03%
6M Prestazione:
-25.79%
1 anno Prestazione:
+46.99%
Intervallo 1D:
$27.70
$30.06
Intervallo di 1 settimana:
$27.70
$30.41
Portata 52W:
$16.88
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Nome
Rigel Pharmaceuticals
Settore
Industria
Telefono
650-624-1100
Indirizzo
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
28.09 | 519.10M | 294.28M | 367.02M | 75.66M | 18.91 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-05 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-04-03 | Ripresa | Piper Sandler | Neutral |
| 2022-06-09 | Downgrade | Citigroup | Buy → Neutral |
| 2022-06-08 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | Iniziato | B. Riley Securities | Neutral |
| 2020-11-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-15 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-09-26 | Ripresa | JP Morgan | Overweight |
| 2019-03-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-08-27 | Iniziato | Citigroup | Buy |
| 2018-05-02 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-12-21 | Ripresa | Piper Jaffray | Overweight |
| 2017-12-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-11-06 | Ripresa | H.C. Wainwright | Buy |
| 2017-03-09 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-31 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-30 | Reiterato | Piper Jaffray | Overweight |
| 2016-07-13 | Iniziato | H.C. Wainwright | Buy |
| 2016-06-13 | Iniziato | Piper Jaffray | Overweight |
| 2016-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2013-04-08 | Reiterato | Stifel | Buy |
| 2012-11-29 | Iniziato | UBS | Neutral |
| 2012-11-06 | Reiterato | Oppenheimer | Outperform |
| 2012-03-26 | Iniziato | Canaccord Genuity | Hold |
| 2010-12-10 | Downgrade | MP Advisors | Outperform → Market Perform |
Mostra tutto
Rigel Pharmaceuticals Borsa (RIGL) Ultime notizie
Rigel Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Rigel Pharmaceuticals reports Q1 EPS 44c, consensus 87c - TipRanks
Rigel Pharmaceuticals : Quarterly Report for Quarter Ending MARCH 31, 2026 (Form 10-Q) - marketscreener.com
Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates - Yahoo Finance
Earnings call transcript: Rigel Pharmaceuticals Q1 2026 sees revenue growth, stock dips - Investing.com
Rigel Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript - Benzinga
Rigel Pharmaceuticals (NASDAQ:RIGL) Q1 2026 Results Miss Revenue and EPS Estimates, Stock Declines After-Hours - ChartMill
Rigel: Q1 Earnings Snapshot - marketscreener.com
Rigel (NASDAQ: RIGL) grows Q1 2026 sales, ends Lilly RIPK1 deal - Stock Titan
Rigel (NASDAQ: RIGL) grows Q1 2026 drug sales, reaffirms 2026 outlook - Stock Titan
Rigel Reports First Quarter 2026 Financial Results - PR Newswire
MSN Money - MSN
Hussman Strategic Advisors Inc. Buys New Shares in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Buys Shares of 55,200 Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
RIGL Stock Price, Quote & Chart | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill
Q1 2026 results and business update set for May 5, Rigel Pharmaceuticals confirms - Traders Union
Earnings Preview: RIGL to Report Financial Results Post-market on May 05 - 富途牛牛
Rigel Pharmaceuticals (RIGL) to report Q1 results: Wall Street expects earnings growth - MSN
Rigel Announces Conference Call and Webcast to Report First Quar - GuruFocus
Is the options market predicting a spike in Rigel Pharmaceuticals stock? - MSN
Rigel Pharmaceuticals (RIGL) to Release Earnings on Tuesday - MarketBeat
Rigel Pharmaceuticals (RIGL) to Report Q1 Results: Wall Street Expects Earnings Growth - Yahoo Finance
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results - Moomoo
RIGEL PHARMACEUTICALS INC (RIGL) Fundamental Analysis & Valuation - ChartMill
Piper Sandler Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Cuts Target Price to $40 - 富途牛牛
Behavioral Patterns of RIGL and Institutional Flows - Stock Traders Daily
Is the Options Market Predicting a Spike in Rigel Pharmaceuticals Stock? - Yahoo Finance
Eli Lilly terminates agreement with Rigel Pharmaceuticals - medwatch.com
Eli Lilly terminates license agreement with Rigel over ocadusertib - MSN
Ruffer LLP Invests $1.60 Million in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
RIGL (Rigel Pharmaceuticals Inc.) climbs two percent after Q4 2025 results, even as EPS falls short of analyst forecasts.Verified Stock Signals - Xã Châu Thành
Biopharma bites: Sarclisa's delayed review, Lilly exits Rigel pact, Amneal's biosimilar buy and more from Sanofi, Ipsen - FirstWord Pharma
Lilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitors - Fierce Biotech
Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Down 5.1%Time to Sell? - MarketBeat
Lilly exits Rigel alliance, adding to RIPK1 scrap heap - BioSpace
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - Moomoo
Eli Lilly Ends Collaboration with Rigel Pharmaceuticals (LLY) - GuruFocus
Rigel Pharmaceuticals Inc on April 16, received written notice from Eli Lilly - marketscreener.com
Rigel Pharmaceuticals Inc On April 16, Received Written Notice From Eli Lilly - TradingView
Rigel Pharmaceuticals to regain rights to ocadusertib after Eli Lilly ends agreement - Investing.com Nigeria
Rigel Regains Rights as Eli Lilly Ends Collaboration - TipRanks
Rigel Pharmaceuticals to Regain Rights as Lilly Terminates RIPK1 License and Collaboration - TradingView
Eli Lilly ends Rigel (RIGL) RIPK1 licensing deal, no future milestones - Stock Titan
Rigel Pharmaceuticals (RIGL) Stock: Reversal Signals (-0.90%) 2026-04-16High Attention Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Rigel Pharmaceuticals, Inc. (RIGL) Stock Analysis: A Biotech Player with 59.70% Upside Potential - DirectorsTalk Interviews
(RIGL) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Why Rigel Pharmaceuticals Lost Big in December - AOL.com
Ritholtz Wealth Management Boosts Rigel Pharmaceuticals Holdings - National Today
Ritholtz Wealth Management Acquires 72,999 Shares of Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Why VAALCO Energy, Rigel Pharmaceuticals, and Companhia Siderurgica Nacional Are Today's 3 Best Stoc - Yahoo
Rigel Pharmaceuticals Azioni (RIGL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):